University of Southern California

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Southern California sits in the top decile of US sponsors by registered trial count (#55 of 15,742 sponsors by registered trial count).

617 total trials 97 currently recruiting 361 completed early-phase tilt top decile by trial count

University of Southern California: 617 sponsored US clinical trials, 97 recruiting.

University of Southern California sponsors 617 registered US clinical trials on ClinicalTrials.gov, 97 of them currently recruiting, and 361 completed. 31 of these trials are in Phase 3-4 (later-stage) and 173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 6 trials.

Top-decile sponsor footprint

University of Southern California ranks in the top decile of sponsors by registered trial count (#55 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 33/100

361 of 466 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

617 total, page 12 of 13

TERMINATED Phase 2

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

NCT00981903

COMPLETED NA

Strength and Nutrition Outcomes for Latino Adolescents

NCT00697580

COMPLETED Phase 2

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

NCT00183937

COMPLETED Phase 2

Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma

NCT00183872

TERMINATED Phase 2

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

NCT00183976

COMPLETED Phase 4

Collaborative Depression Care Management in Treating Depressed Low-income Hispanics With Diabetes

NCT00709150

COMPLETED Phase 2

Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer

NCT00159432

TERMINATED NA

Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.

NCT00159471

COMPLETED Phase 2

Does Reducing Spasticity Permit an Increase in Strength?

NCT00255073

COMPLETED NA

USC Well Elderly Study 2

NCT00786344

COMPLETED Phase 2

Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma

NCT00183820

COMPLETED Phase 2

A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma

NCT00183885

COMPLETED Phase 1

Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer

NCT00159484

TERMINATED Phase 2

Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck

NCT00184028

TERMINATED NA

The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors

NCT01224509

COMPLETED Phase 2

Intensified Post Remission Therapy Containing PEG-Asparaginase

NCT00184041

COMPLETED Phase 2

ELITE: Early Versus Late Intervention Trial With Estradiol

NCT00114517

COMPLETED NA

Treating Depression Among Low-Income Patients With Cancer

NCT00565110

COMPLETED Phase 2

Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00184080

COMPLETED Phase 2

Strength Training Effectiveness Post-Stroke (STEPS)

NCT00389012

COMPLETED Phase 2

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

NCT00085189

TERMINATED Phase 2

Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma

NCT00184067

COMPLETED Phase 2

Women's Isoflavone Soy Health (WISH) Trial

NCT00118846

COMPLETED Phase 1

Prevention of Post-Stroke Hand/Wrist Flexion Deformity

NCT00628537

COMPLETED Phase 2

Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer

NCT00159445

COMPLETED Phase 1

Study of Strengthening Exercises and Improving Movement for Painful Shoulders in Adults With Spinal Cord Injury

NCT00461474

COMPLETED Phase 2

Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma

NCT00183911

COMPLETED Phase 2

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00334776

TERMINATED Phase 2

A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer

NCT00183807

COMPLETED NA

Study of a Stationary Cycling Intervention for Children With Spastic Diplegic Cerebral Palsy

NCT00401154

TERMINATED Phase 2

Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer

NCT00159458

COMPLETED Phase 1

Rehabilitation Post Lumbar Microdiscectomy

NCT00306423

COMPLETED NA

Brain and Behavior Correlates of Arm Rehabilitation

NCT04989920

COMPLETED Phase 4

Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding

NCT01006824

COMPLETED Phase 2

Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas

NCT00184002

COMPLETED Phase 2

Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects

NCT00122044

COMPLETED Phase 1

Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors

NCT00183833

COMPLETED Phase 2

Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma

NCT00183794

TERMINATED NA

Early Colonoscopy for Lower Gastrointestinal (GI) Bleeding

NCT01031342

COMPLETED Phase 1

Exercise and Shoe Orthoses in Treatment of Posterior Tibial Tendon Dysfunction

NCT00279630

TERMINATED Phase 2

Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia

NCT00184054

COMPLETED Phase 2

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

NCT00031733

COMPLETED NA

A Comparison of the Studer Pouch Versus the T-Pouch Orthotopic Neobladder Urinary Diversion in Bladder Cancer Patients

NCT01008865

COMPLETED Phase 1

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

NCT00025181

COMPLETED Phase 1

Novel Adjuvants for Peptide-Based Melanoma Vaccines

NCT00028431

COMPLETED Phase 1

Treatment of Shoulder Subluxation in Chronic Stroke Patients

NCT00628836

COMPLETED Phase 2

Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.

NCT00183924

COMPLETED Phase 1

Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers

NCT00183846

COMPLETED Phase 1

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

NCT00183742

TERMINATED Phase 2

Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma

NCT00183989

← Previous Page 12 of 13 Next →

Phase Distribution

PhaseTrial count
Phase 1 83
Phase 2 90
Phase 3 9
Phase 4 22

What is open in the University of Southern California pipeline

97 recruiting of 617 indexed (16% open); 361 completed (59%).

Phase mix: 31 late (III/IV) vs 173 early (I/II) (early-phase heavy).

Top condition: Obesity (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Southern California: open-pipeline peers nationwide

Peers matched on 617 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of Southern California sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%5%10%15%20% Total trials Recruiting share University of Southern CaliforniaBaylor College of MedicineUS Department of Veterans AffairsUniversity of RochesterJanssen Research & DevelopmentYoungstown State UniversityRoswell Park Cancer InstituteFox Chase Cancer CenterUniversity of Oregon
University of Southern California sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Southern California sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 617 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of Southern California page

617 registered trials is a research-attention snapshot, not an endorsement of University of Southern California or any single study.

  • 97 of University of Southern California's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Southern California studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Southern California pipeline card: 617 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.